Orally-taken meal supplementing medicament for treating osteoarthritis

A dietary supplement, osteoarthritis technology, applied in the fields of application, food science, food ingredients, etc., can solve the problems of increasing the pain of patients, not describing the use of magnesium and its compounds, associated with joint infections, etc., achieving low cost and high cost. Selective, good compliance effects

Inactive Publication Date: 2018-11-02
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the method of intra-articular drug administration is relatively complicated, and repeated articular puncture will increase the pain of patients and may be accompanied by the possibility of joint infection. Therefore, intra-articular injection of magnesium sulfate in the treatment of OA has certain li

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Orally-taken meal supplementing medicament for treating osteoarthritis
  • Orally-taken meal supplementing medicament for treating osteoarthritis
  • Orally-taken meal supplementing medicament for treating osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0029] Example Magnesium and its compound Dietary Supplement Pharmacy Animal Experiment Verification of Curative Effects on Osteoarthritis

[0030] 1 Experimental materials and methods

[0031] 1.1 Drugs and reagents

[0032] Ordinary rat feed (magnesium element content is 0.255g / kg)

[0033] Add the rat feed (magnesium element content is 2.55g / kg) of magnesia dietary supplement medicament

[0034] 1.2 Experimental animals

[0035] Adult male Sprague-Dawley (SD) rats (about 500g in weight)

[0036] 1.3 Experimental method

[0037] 1.3.1 Surgical Modeling

[0038] Knee OA model was constructed by right knee medial collateral ligament, anterior cruciate ligament transection and medial meniscectomy. This model has been validated to induce knee osteoarthritis and represents a good example of experimental degenerative osteoarthritis for pharmacological evaluation of tested drugs.

[0039] 1.3.2 Grouping and administration

[0040] After modeling, the rats were randomly divi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses orally-taken meal supplementing medicament for treating osteoarthritis. The orally-taken meal supplementing medicament for treating osteoarthritis contains magnesium, so that the cartilage damage degree of a rat OA model can be relieved, and the orally-taken meal supplementing medicament for treating osteoarthritis is effective for reducing cartilage matrix degradation, reducing cartilage surface damage degree, and relieving cartilage degrading.

Description

technical field [0001] The present invention relates to an oral dietary supplement for the treatment of osteoarthritis. technical background [0002] Osteoarthritis (OA) is a joint degenerative disease characterized by degeneration of articular cartilage, subchondral bone sclerosis and osteophyte formation, and is mainly characterized by joint pain, limited mobility and joint deformation after activities. Clinical manifestations, often involving weight-bearing joints. Epidemiological surveys in my country show that the prevalence of OA in people over 65 years old exceeds 50%, about 80% of OA patients have a certain degree of movement limitation, and 25% of OA patients are significantly affected in daily life. The cost of treating OA may be as high as 150 billion yuan. Among people over 50 years old in the United States, the disability rate of OA ranks second among all diseases, second only to cardiovascular diseases. With the increase of aging population and obese populati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A23L33/10A23L33/125A23L33/16A23L33/17
CPCA23V2002/00A23L33/10A23L33/125A23L33/16A23L33/17A23V2200/30A23V2250/161A23V2250/5422
Inventor 雷光华刘韶曾超李辉杨拓崔洋丁翔魏捷
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap